Zinc sulphate: A reasonable choice for depression management in patients with
multiple sclerosis: A randomized, double-blind, placebo-controlled clinical
trial.
Author(s): Salari S(1), Khomand P(2), Arasteh M(3), Yousefzamani B(4), Hassanzadeh K(5).
Affiliation(s): Author information:
(1)Student Research Committee, Kurdistan University of Medical Sciences,
Sanandaj, Iran. (2)Department of Neurology, Tohid Hospital, Kurdistan University
of Medical Sciences, Sanandaj, Iran. (3)Department of Psychiatry, Faculty of
Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. Electronic
address: modabber.arasteh@muk.ac.ir. (4)Besat Hospital, Kurdistan University of
Medical Sciences, Sanandaj, Iran. (5)Cellular and Molecular Research Center,
Kurdistan University of Medical Sciences, Sanandaj, Iran; Department of
Physiology and Pharmacology, Faculty of Medicine, Kurdistan University of Medical
Sciences, Sanandaj, Iran. Electronic address: kambizhassanzadeh@gmail.com.
Publication date & source: 2015, Pharmacol Rep. , 67(3):606-9
INTRODUCTION: Major Depressive Disorder (MDD) is known as one of the most common
psychiatric disorders in patients with multiple sclerosis (MS). In recent years,
zinc has been found to have beneficial effects on psychopathology and the therapy
of depression. The aim of the present study was to examine the effect of zinc
supplement on depression and neurological signs in patients with MS.
METHODS: The present randomized, double-blind, placebo-controlled clinical trial
was performed on 43 patients with MS and who also demonstrated MDD based on the
Beck questionnaire. These patients were randomly selected and were divided into
two groups: the placebo group (n=22) and the intervention group (n=21). The
patients received either zinc sulphate (220 mg containing 50mg zinc element) or a
placebo for 12 weeks. Clinical examinations were obtained in terms of abnormal
ocular movement, muscle power, and gait disorder.
RESULTS: The results indicated that in the patients who received the zinc
supplement, the mean score of depression was reduced compared to those in the
placebo group, whereas the neurological examinations revealed that there were no
differences between the treatment and control groups.
CONCLUSION: Therefore, the zinc supplementation is an appropriate choice for the
depression management in patients with MS.
|
